Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

NACompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2017

Study Completion Date

October 31, 2017

Conditions
HIV InfectionsStaphylococcal Infections
Interventions
DRUG

Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%

"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."

DRUG

Placebo

Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.

Trial Locations (4)

20889

Walter Reed National Military Medical Center, Bethesda

92134-1201

Naval Medical Center San Diego/Infectious Disease Division, San Diego

78236-9908

San Antonio Military Medical Center (BAMC/WHMC), San Antonio

23708-2197

Naval Medical Center Portsmouth, Portsmouth

All Listed Sponsors
collaborator

Infectious Diseases Clinical Research Program

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

US Military HIV Research Program

NETWORK

lead

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

NCT00631566 - Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons | Biotech Hunter | Biotech Hunter